Please login to the form below

Not currently logged in


This page shows the latest beloranib news and features for those working in and with pharma, biotech and healthcare.

Zafgen shares tumble after FDA places hold on diabetes trial

Zafgen shares tumble after FDA places hold on diabetes trial

Like beloranib, ZGN-1061 is an injectable small molecule drug that is supposed to help the body burn more fat by inhibiting the activity of the methionine aminopeptidase 2 (MetAP2) enzyme. ... Zafgen came close to running out of cash when it was forced

Latest news

  • Second patient death in Zafgen's obesity drug trial

    A second patient enrolled in a phase III trial of Zafgen's obesity drug candidate beloranib has died, placing the future of the programme in doubt. ... Analysts suggested that the toxicity concern could give beloranib a tough time getting through

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...